CA
TEVA icon

Centerpoint Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Centerpoint Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-107
Closed -$1K – 587
2023
Q3 		$1K Hold
107
– – ﹤0.01% 543
2023
Q2 		$1K Hold
107
– – ﹤0.01% 542
2023
Q1 		$1K Buy
+107
New +$1.06K ﹤0.01% 536

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Centerpoint Advisors's TEVA Position: Q4 2023 in Review

Centerpoint Advisors sold out of Teva Pharmaceuticals (TEVA) in Q4 2023, closing a stake of 107 shares — an estimated $1K sold.

Centerpoint Advisors first reported a position in TEVA in Q1 2023 and held it in 3 quarters. The position peaked at $1K in Q3 2023. 447 funds tracked by Wall St. Rank hold TEVA as of Q4 2023.

  • Centerpoint Advisors reported no remaining Teva Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Centerpoint Advisors sold 107 Teva Pharmaceuticals shares in Q4 2023, an estimated $1K.
  • Centerpoint Advisors first reported a position in Teva Pharmaceuticals in Q1 2023 and held it in 3 quarters.
  • Centerpoint Advisors's Teva Pharmaceuticals position peaked at $1K in Q3 2023.
  • 447 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2023.

Based on Centerpoint Advisors's 13F filing for Q4 2023, filed 16 Jan 2024.